semaglutide and cardiovascular outcomes in obesity without diabetes journal club Weight loss disease risk of semaglutide: a one-year multicentered study Insights into semaglutide cardiovascular research:

It is marketed as Ozempic (injectable, diabetes), Wegovy (injectable, obesity), and Rybelsus (oral, with SNAC absorption enhancer)

While weight regain is common, the degree varies - and the people who tend to have better outcomes are those who have built strong nutritional and lifestyle habits alongside the medication, and who have support in place for the transition

Patients who experience steady results may remain more engaged in their overall wellness plan, supporting outcomes that persist beyond initial weight loss phases

Its important to talk to your prescriber about potential adverse events before taking and while using semaglutide